ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus

Subroto Chatterjee1, Michelle Petri2, Steven Jones3 and Vignesh Sadras1, 1Pediatrics-Cardiology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: lipids and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Oxidized Phospholipids, Lipoprotein (a) and Glycosphingolipid Associated B- 1,4 Galactosyltransferase in a Johns Hopkins cohort of patients with Systemic Lupus Erythematosus.

Background/Purpose: Systemic lupus erythematosus(SLE) is an autoimmune disease wherein the patient’s immune system attacks apparently healthy tissue. These patients develop atherosclerotic plaques,and have high rates of coronary events mostly in premenopausal women. Chronic inflammation, lipid oxidation, and production of reactive oxygen species may attribute to atherosclerosis in these patients but this relationship has not been tested. We have previously shown that oxidized phospholipids(Ox-PC) could activate B-1,4galactosyltransferase to generate a glycosphingolipid, lactosylceramide which in turn, produces reactive oxygen species in vascular cells implicated in cell proliferation, angiogenesis, and migration-hallmarks in the pathophysiology of atherosclerosis.

Methods: SLE patients form the Johns Hopkins University cohort were assessed for disease activity using the Physician Global Assessment, the SELDA, and organ involvement assessments (the SLICC/ACR Damage index). Further, laboratory tests were condcuted to ascertain organ damage, and cardiovascular risk factors. Hopkins institutional board approval was obtained for this study. The SLE patients serum(N=50) were 50% Caucasian and 40% African American women with mean age of 38. Control serum(N=50) was obtianed from 90% Caucasian and 10% African American women with the mean age of 38. Serum levels of Ox-PC per apoB-100particle (Ox-PC-apoB) was measured by ELISA using a murine monoclonal antibody EO6,which binds to the phosphorylcholine group of oxidized phospholipids but not to native phospholpipids. By the use of apoB antibody an equal number of apoB particles in serum were captured first and then Ox-PC level was measured. The serum levels of lipoprotein a(Lp(a) and B-1,4galactosyltransferase(B-1,4GalT-V) were also measured by ELISA using corresponding antibody raised against these antigens.

Results: We observed that there were more Ox-PC molecules per apoB protein in the serum of SLE patients as compared to control serum. This was highly statistically significant(p<0.0001). Since Lp(a) on apoB protein is the major carrier of OX-PC,it was not surprising to observe that the level of Lp(a) were also significantly increased in SLE serum (p< 0.0001). An unexpected finding was that the B-1,4GalT-V mass was also increased (p<0.0001) in SLE serum relative to control serum.

Conclusion: This study demonstrates that increased level of Ox-PC,Lp(a) and B-1,4GalT-V predict the pro-atherogenic and pro-inflammatory potential of these biomarkers in SLE.


Disclosure: S. Chatterjee, None; M. Petri, None; S. Jones, None; V. Sadras, None.

To cite this abstract in AMA style:

Chatterjee S, Petri M, Jones S, Sadras V. Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/oxidized-phospholipidslipoproteina-and-glycosphingolipid-associated-b-14-galactosyltransferase-in-a-johns-hopkins-cohort-of-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxidized-phospholipidslipoproteina-and-glycosphingolipid-associated-b-14-galactosyltransferase-in-a-johns-hopkins-cohort-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology